University of Pittsburgh PITT HOME  |  FIND PEOPLE  |  CONTACT US
  Pittsburgh Molecular Libraries Screening Center
HOME
HISTORY
SCREENING TECHNOLOGY
COMPOUND LIBRARIES
INSTRUMENTATION/PLATFORMS
HTS GUIDELINES
APPROVED PMLSC ASSAY PROTOCOLS
  • PMLSC Assay Protocol Review Document for MKP-1 HTS
  • PMLSC Assay Protocol Review Document for Cdc25B Catalytic Domain HTS
  • GNHR Translocation Assay APAC Review document
  • Necroptosis PMLSC APAC Document
  • PLK-1 PBD PMLSC APAC Document
  • West Nile Virus NS2bNS3 PMLSC APAC Document
  • Time Resolved Fluorescence Resonance Energy Transfer assay for Plk1 inhibitors
  • PKD IMAP TR-FRET APAC Document
  • High-content cell-based screening for modulators of autophagy
  • MKP-3 Chemical Complementation assay
  • PMLSC PROBE REPORTS
    DATA ANALYSIS/INFORMATICS
    PUBLICATIONS
    LINKS
    CONTACTS
    Approved PMLSC Assay Protocols
     
    bullet point  Time Resolved Fluorescence Resonance Energy Transfer assay for Plk1 inhibitors
     
     
    Polo-like kinase 1 (Plk1) is a serine-threonine protein kinase that functions as a key regulator of mitosis/meiosis and cytokinesis (Barr et al., 2004). Numerous research studies have demonstrated that Plk1 gene expression is frequently up-regulated in human cancers and carcinoma-derived cell lines (Simizu and Osada, 2000). Plk1 expression levels are abnormal in many spontaneous human cancers including pancreatic, ovarian, breast, non-small cell lung carcinoma, prostate, melanoma, colorectal, and gliomas (Weichert et al., 2004; Weichert et al., 2005; Takai et al., 2005). Interest in Plk1 is based on evidence that Plk1 inhibition by Plk1-specific anti-sense oligonucleotides, siRNA, or short hairpin RNA results in decreased tumor-derived cell survival and inhibited tumor growth in animal models (Spankuch-Schmitt et al., 2002; Spankuch et al., 2004; Guan et al., 2005). These data suggest that Plk1 is a rational and validated anticancer drug target. Interestingly, there is evidence that Plk1 is a molecular target for other diseases and/or viral infections. For example, it has been shown that Plk1 protein is (1) along with other cell cycle proteins, detectable in Alzheimer’s, but not in control neurons (Harris et al., 2000; Husseman et al., 2001); (2) up-regulated in CD4+ T cells from rhesus macaques infected with high viral load SIV (Bostik et al., 2004); (3) up-regulated in primary human kertinocytes infected with human papilloma virus type 16 E6 and E7 (Patel et al., 2004); and (4) is specifically associated with and/or phosphorylates the human cytomegalovirus pp65 lower matrix protein upon infection of human fibroblasts and HeLa cells (Gallina et al., 1999). While the significance of these latter findings is undefined, it suggests that aberrant Plk1 expression may result in unregulated cell cycle events leading to cell degeneration or that pathogenic viruses express and/or recruit Plk1 for their own benefit.
     
    Documents
  • Time Resolved Fluorescence Resonance Energy Transfer assay for Plk1 inhibitors APAC Document
  •  
      to topto top
     
     
       Health Sciences @ Pitt   |    UPMC   |    HSLS   |    School of Medicine   |    Health Sciences Calendar   |    Our News & Events  
    Top of Page  |  Home  |  Contact Us Last Update 4/29/2008
    © Office of the Senior Vice Chancellor for Health Sciences, University of Pittsburgh. All rights reserved.